Screener
United Therapeutics UTHR Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by United Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherLiabilitiesCurrent.
The source filing: United Therapeutics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 6:31 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001082554-26-000027
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable and accrued expenses | $497.8 | $488.0 |
| Other current liabilities | 110.0 | 72.6 |
| Total current liabilities | 607.8 | 560.6 |
| Other non-current liabilities | 212.0 | 223.2 |
| Total liabilities | 819.8 | 783.8 |
| Commitments and contingencies |
Item 1. Consolidated Financial Statements
FAQ
- What is United Therapeutics's accrued expenses?
- United Therapeutics (UTHR) reported accrued expenses of $110M in Q2 2026.
- How has United Therapeutics's accrued expenses changed year-over-year?
- United Therapeutics's accrued expenses increased by 15.7% year-over-year, from $95.1M to $110M.
- What is the long-term trend for United Therapeutics's accrued expenses?
- Over 5 years (2020 to 2025), United Therapeutics's accrued expenses has grown at a 12.9% compound annual growth rate (CAGR), from $39.5M to $72.6M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.
Ask your AI about United Therapeutics's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude